Carbone M, Kratzke RA, Testa JR: The pathogenesis of mesothelioma. Semin Oncol. 2002, 29 (1): 2-17. 10.1053/sonc.2002.30227
Article
CAS
PubMed
Google Scholar
Peto J, Decarli A, La Vecchia C, Levi F, Negri E: The European mesothelioma epidemic. Br J Cancer. 1999, 79: 666-672. 10.1038/sj.bjc.6690105
Article
PubMed Central
CAS
PubMed
Google Scholar
Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E: The Mesothelioma epidemic in Western Europe: an update. Br J Cancer. 2004, 90 (5): 1022-1024. 10.1038/sj.bjc.6601638
Article
PubMed Central
CAS
PubMed
Google Scholar
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21 (14): 2636-2644. 10.1200/JCO.2003.11.136
Article
CAS
PubMed
Google Scholar
Gralla RJ, Hollen PJ, Liepa AM, Symanowski JT, Boyer MJ, Abraham R, Rusthoven JJ, Paz-Ares L, Vogelzang NJ: Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized premetrexed and cisplatin vs. cisplatin trial using the LCSS-meso instrument. Proc Am Soc Clin Oncol. 2003, 22: 621-
Google Scholar
Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004, 22 (17): 3451-3457. 10.1200/JCO.2004.10.071
Article
CAS
PubMed
Google Scholar
Igney FH, Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002, 2 (4): 277-288. 10.1038/nrc776
Article
CAS
PubMed
Google Scholar
Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002, 108 (2): 153-164. 10.1016/S0092-8674(02)00625-6
Article
CAS
PubMed
Google Scholar
Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML: Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem. 2000, 275 (30): 23319-23325. 10.1074/jbc.M910438199
Article
CAS
PubMed
Google Scholar
Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002, 2 (6): 420-430. 10.1038/nrc821
Article
CAS
PubMed
Google Scholar
Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005, 5 (11): 876-885. 10.1038/nrc1736
Article
CAS
PubMed
Google Scholar
Rowinsky EK: Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 2005, 23 (36): 9394-9407. 10.1200/JCO.2005.02.2889
Article
CAS
PubMed
Google Scholar
Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 2005, 92 (8): 1430-1441. 10.1038/sj.bjc.6602487
Article
PubMed Central
CAS
PubMed
Google Scholar
Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000, 102 (1): 1-4. 10.1016/S0092-8674(00)00003-9
Article
CAS
PubMed
Google Scholar
Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, Jang JJ, Nam SW, Lee JY, Yoo NJ: Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non- Hodgkin's lymphoma. Oncogene. 2001, 20 (3): 399-403. 10.1038/sj.onc.1204103
Article
CAS
PubMed
Google Scholar
Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S: Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005, 5 (1): 54. 10.1186/1471-2407-5-54
Article
PubMed Central
PubMed
Google Scholar
Tschopp J, Irmler M, Thome M: Inhibition of fas death signals by FLIPs. Curr Opin Immunol. 1998, 10 (5): 552-558. 10.1016/S0952-7915(98)80223-9
Article
CAS
PubMed
Google Scholar
Scaffidi C, Schmitz I, Krammer PH, Peter ME: The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 1999, 274 (3): 1541-1548. 10.1074/jbc.274.3.1541
Article
CAS
PubMed
Google Scholar
Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC: A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol. 2005, 33 (6): 541-548. 10.1165/rcmb.2004-0355OC
Article
PubMed Central
CAS
PubMed
Google Scholar
Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, Amici G, Catalano A, Procopio A: FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene. 2004, 23 (47): 7753-7760. 10.1038/sj.onc.1208051
Article
CAS
PubMed
Google Scholar
Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC: Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol. 2001, 25 (1): 111-118.
Article
CAS
PubMed
Google Scholar
Tomasetti M, Rippo MR, Alleva R, Moretti S, Andera L, Neuzil J, Procopio A: Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. Br J Cancer. 2004, 90 (8): 1644-1653. 10.1038/sj.bjc.6601707
Article
PubMed Central
CAS
PubMed
Google Scholar
Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, de Vries EG: The clinical trail of TRAIL. Eur J Cancer. 2006, 42 (14): 2233-2240. 10.1016/j.ejca.2006.03.018
Article
CAS
PubMed
Google Scholar
Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, Stahel R: p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia. 2006, 8 (7): 551-559. 10.1593/neo.06148
Article
PubMed Central
CAS
PubMed
Google Scholar
Schmitter D, Lauber B, Fagg B, Stahel RA: Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992, 51: 296-301. 10.1002/ijc.2910510220
Article
CAS
PubMed
Google Scholar
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995, 3 (6): 673-682. 10.1016/1074-7613(95)90057-8
Article
CAS
PubMed
Google Scholar
Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science. 1998, 281 (5381): 1305-1308. 10.1126/science.281.5381.1305
Article
CAS
PubMed
Google Scholar
MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM: TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 2005, 65 (24): 11265-11270. 10.1158/0008-5472.CAN-05-2801
Article
CAS
PubMed
Google Scholar
Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C: Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene. 2006, 25 (37): 5145-5154.
CAS
PubMed
Google Scholar
Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. British journal of haematology. 2005, 130 (4): 501-510. 10.1111/j.1365-2141.2005.05656.x
Article
CAS
PubMed
Google Scholar
Kim YH, Lee YJ: Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. J Cell Biochem. 2006, 98 (5): 1284-1295. 10.1002/jcb.20844
Article
CAS
PubMed
Google Scholar
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002, 277 (5): 3247-3257. 10.1074/jbc.M106643200
Article
CAS
PubMed
Google Scholar
Stewart JH, Tran TL, Levi N, Tsai WS, Schrump DS, Nguyen DM: The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma. The Journal of surgical research. 2007, 141 (1): 120-131. 10.1016/j.jss.2007.03.048
Article
CAS
PubMed
Google Scholar
Freeman RE, Neuzil J: Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells. FEBS Lett. 2006, 580 (11): 2671-2676. 10.1016/j.febslet.2006.04.019
Article
CAS
PubMed
Google Scholar
Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A: Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005, 280 (3): 2205-2212. 10.1074/jbc.M410660200
Article
CAS
PubMed
Google Scholar
Neuzil J, Swettenham E, Gellert N: Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun. 2004, 314 (1): 186-191. 10.1016/j.bbrc.2003.12.074
Article
CAS
PubMed
Google Scholar
Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P: Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene. 2003, 22 (19): 2869-2881. 10.1038/sj.onc.1206427
Article
CAS
PubMed
Google Scholar
van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005, 23 (28): 6881-6889. 10.1200/JCO.20005.14.589
Article
CAS
PubMed
Google Scholar
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2003, 21 (14): 2636-2644. 10.1200/JCO.2003.11.136
Article
CAS
PubMed
Google Scholar
Wu XX, Ogawa O, Kakehi Y: TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm. 2004, 67: 365-383.
Article
CAS
PubMed
Google Scholar
Petak I, Houghton JA: Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res. 2001, 7 (2): 95-106.
Article
CAS
PubMed
Google Scholar
Kondo K, Yamasaki S, Sugie T, Teratani N, Kan T, Imamura M, Shimada Y: Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer. 2006, 118 (1): 230-242. 10.1002/ijc.21283
Article
CAS
PubMed
Google Scholar
Kim JH, Ajaz M, Lokshin A, Lee YJ: Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Clin Cancer Res. 2003, 9 (8): 3134-3141.
CAS
PubMed
Google Scholar
Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998, 161 (6): 2833-2840.
CAS
PubMed
Google Scholar
Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ, Bueno R: Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol. 2007, 211 (4): 447-454. 10.1002/path.2121
Article
CAS
PubMed
Google Scholar
Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA: Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. 2005, 65 (16): 7436-7445. 10.1158/0008-5472.CAN-04-2628
Article
CAS
PubMed
Google Scholar
Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ, Choi KS: Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res. 2006, 66 (3): 1740-1750. 10.1158/0008-5472.CAN-05-1568
Article
CAS
PubMed
Google Scholar
Nguyen DM, Yeow WS, Ziauddin MF, Baras A, Tsai W, Reddy RM, Chua A, Cole GW, Schrump DS: The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death. Cancer journal (Sudbury, Mass. 2006, 12 (4): 257-273.
Article
CAS
Google Scholar
Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000, 60 (11): 2805-2809.
CAS
PubMed
Google Scholar
Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003, 10 (3): 356-364. 10.1038/sj.cdd.4401157
Article
CAS
PubMed
Google Scholar